Generic Acomplia (Rimonabant, Acomplia® equivalent)
Rimonabant is an anorectic anti-obesity medication. It is a CB1 cannabinoid receptor antagonist. Rimonabant has been found effective in stopping food craving, and is used to assist in losing weight. It is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, and recently was also proven effective in smoking cessation. This is a non-controlled weight loss solution with proven results.
This product will arrive to you in 14-24 business days (free shipping worldwide)
20mg
| Quantity | Price | Price per pill | Returning customer price | Bonus |
|---|
Drug Medical Information
HOW COMMON IS OBESITY?
Severe obesity was rare in the first half of the twentieth century and was more commonly associated with the affluent classes, although some unfortunate obese individuals were displayed in 'freak shows' by travelling circuses.
Since the beginning of the twentieth century there has been a linear increase in the average BMI of the population, although in the past 50 years the prevalence of obesity has increased so rapidly that in many developed nations to be overweight is to be in the majority, and to be obese is no longer unusual. In the UK between 1980 and 1997, levels of overweight in men increased from 39 to 62%, and in women from 32 to 53%. In the same time period, obesity in men increased three-fold from 6 to 17%, and in women levels rose from 8 to 20%. Recent UK figures put obesity levels at 22% for men and women. Similar patterns have been observed in the majority of developing nations. In the US current estimates put the prevalence of overweight in adults at 61%, and of obesity at 26%.
What is clear is that levels of obesity have been escalating rapidly and have reached epidemic proportions in many nations and throughout the world in general. If this was solely a cosmetic problem we would have little to fear. However, with the increasing prevalence of overweight and obesity has come a dramatic increase in obesity-related disease. Type 2 diabetes is the most commonly associated health risk and in the UK the current number of around 1.5 million type 2 diabetics is expected to double to 3 million over the next 10 years. We are therefore faced with a disease of epidemic proportions, with hugely significant implications for individuals, health services and national economies.
*2/312/5*
